ArticleBMC pediatrics2025
Global burden of hemolytic disease and neonatal jaundice from 1990 to 2021 with projections to 2050: a systematic analysis of the GBD 2021 data.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal hemolytic disease and jaundice represent a persistent global health challenge, accounting for substantial avoidable mortality and long-term neurodevelopmental impairment among infants worldwide, with inequitable impacts across resource regions. This study aimed to evaluate the global, regional, and national burden of hemolytic disease and neonatal jaundice from 1990 to 2021, and project future trends up to 2050.
methodsData on prevalence, disability-adjusted life years (DALYs), and risk factors were drawn from the Global Burden of Disease (GBD) 2021 study. Socio-demographic disparities were assessed via the socio-demographic index (SDI). Temporal trends were examined, inequalities were quantified by the slope index of inequality and concentration index, and future burden was projected to 2050.
resultsGlobally, the ASPR of neonatal jaundice increased by 41.5% between 1990 and 2021, while ASDR decreased by 56.8%. DALYs declined overall, but absolute case numbers rose due to population growth and improved survival. The burden was consistently higher in males than females and disproportionately concentrated in low and middle SDI regions. Key risk factors included low birthweight, preterm birth, and air pollution. Projections suggest that prevalence will continue to rise through 2050, while mortality is expected to decline further.
conclusionsA global trend of increasing ASPR but decreasing ASDR from neonatal jaundice-related conditions was found. However, low SDI regions still have a disproportionate burden, underscoring the urgent need for targeted perinatal interventions and mitigation of environmental risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.